Tag:
propofol
Latest Headlines
Latest Headlines
Hospira says temporary production glitch affecting propofol supplies
Production has resumed but CEO Michael Ball said it "has created a temporary shortage situation with Propofol and also impacted certain contract manufacturing customers."
Teva expected to pay big bucks for decision to use oversized vials
Teva Pharamaceuticals ( $TEVA ) is discovering size matters. The Israeli generics giant reportedly is setting aside $285 million to settle lawsuits alleging the jumbo-sized vials it used for its...
Teva wraps up most propofol suits for $285M
Teva Pharmaceutical Industries ( $TEVA ) is closing in on the last chapter of its propofol litigation.
Surgeon sues Allergan over large Botox vials
Las Vegas appears to be becoming an epicenter of protest against large vials of injectable drugs. A plastic surgeon in that city has sued Allergan ( $AGN ), saying the drugmaker is marketing Botox in
APP taps parent Fresenius' facilities to boost propofol supply
APP Pharmaceuticals ( $APPX ) has boosted production of propofol , long on the FDA's list of drugs in short supply, and reports its two versions of the drug are "readily available." The drugmaker, a
APP Pharma boosts supply of propofol products
APP Pharmaceuticals ( $APPX ) has ramped up production of two versions of propofol, an anesthetic that has been in short supply over the past year. Report
Teva walloped $163M in hepC ruling, doc 'unfit' for trial
The other shoe has dropped for Teva ( $TEVA ) and supply chain partners Baxter ( $BAX ) and McKesson ( $MCK ) in the case of a hepatitis C outbreak that followed reuse of jumbo-sized vials of propofol at a
Third jury rules against Teva, Baxter in hep C suit
A third Nevada jury has ruled against Teva Pharmaceuticals ( $TEVA) and Baxter International ( $BAX ). The panel ordered the two companies to pay $14 million for selling large vials of propofol, an
Jury adds $162M to damages in Teva case
These are the kinds of big numbers a drugmaker doesn't want to see. The Nevada jury that delivered a $20 million verdict against Teva Pharmaceutical Industries ( $TEVA ) and its co-defendants last week
Teva, partners fined $20M in second propofol/Hep-C case
Generics-maker Teva ( $TEVA ), its partner Baxter ( $BAX ) and distributor McKesson ( $MCK ) have been ordered to pay $20 million to three Las Vegas colonoscopy patients who contracted hepatitis C
